logo-novo

What is the link between GLP-1 and appetite regulation?

Homeostatic responses to weight regulation include changes to behavioural and psychological systems that control energy expenditure and appetite. As part of these responses, the human body secretes several hormones that regulate appetite.1

When food is consumed, hormones such as ghrelin and leptin, and additional hormones such as GLP-1, are released into the bloodstream and may affect several areas of the brain, influencing feelings of satiety and hunger.1-5

Saxenda® is an analog of human GLP-1, a physiological regulator of appetite and food intake5*

Photo hormone



* Clinical significance unknown.
† Data from a 5-week pharmacodynamic trial of 49 obese (BMI 30–40 kg/m2) non-diabetic patients. Appetite sensations were assessed before and up to five hours after a standardized breakfast meal, and ad libitum food intake during the subsequent lunch meal.

GLP-1 = glucagon-like peptide-1.

 

References:

  1. Torekov SS, et al. Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. Obes Rev. 2011;12(8):593-601.
  2. Suzuki K, et al. Obesity and appetite control. Exp Diabetes Res. 2012;2012:824305.
  3. Stangor C, et al. Introduction to Psychology - 1st Canadian Edition: B.C. Open Textbook 2014.
  4. Gonzalez-Muniesa P, et al. Obesity. Nat Rev Dis Primers. 2017;3:17034.
  5. Saxenda® Product Monograph. Novo Nordisk Canada Inc. April 24, 2024.

 

Contact Us  | Privacy Policy | Terms of Use


All trademarks and registered trademarks are the property of their respective owners.
Saxenda®, SaxendaCare®, NovoFine®, and Apis Bull Design® are registered trademarks of Novo Nordisk A/S used under licence by Novo Nordisk Canada Inc.
Novo Nordisk Canada Inc., tel: (905) 629-4222 or 1-800-465-4334.
© Novo Nordisk Canada Inc.
CA24SX00010E